Young people (15 to 24 years) especially likely to drop out of HIV care
Eviplera works well regardless of viral load or CD4 count, may improve lipid levels
Unravelling the mystery of the vaccine trials
HIV monitoring every six months is adequate for people on ART with stable viral suppression
Specialised testing and social marketing campaigns increase the detection of acute HIV infection among gay men
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen
Researchers see further positive results with herpes virus-based vaccines in monkeys
Female condom choices are expanding – new models have low failure rates and are acceptable to users
The monkeys’ tale – how a vaccine might nip HIV in the bud
